lobbying_activities: 2152031

Individual lobbying activities reported in quarterly filings. Each row is one issue area for one client — includes the specific issues lobbied on, government entities contacted, and income/expense amounts.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

This data as json

id	filing_uuid	filing_type	registrant_name	registrant_id	client_name	filing_year	filing_period	issue_code	specific_issues	government_entities	income_amount	expense_amount	is_no_activity	is_termination	received_date
2152031	92683c5b-e7cb-4e3a-9bf0-56bca99ce957	Q2	HOOPER, LUNDY & BOOKMAN, P.C.	401020884	BROWN RUDNICK, LLP, ON BEHALF OF PRIME THERAPEUTICS	2018	second_quarter	MMM	H.R. 1316-The Prescription Drug Price Transparency Act (MAC); H.R. 1038 & S.413-Improving Transparency and Accuracy in Medicare Part D Drug Spending Act (DIR); H.R. 1939 & S. 1044 - Ensuring Seniors Access to Local Pharmacies Act of 2017; S. 2553-Know the Lowest Price Act. CY2019 Medicare Part D Final Rule relating to direct and indirect renumeration fees; H.R.5958-The Phair Pricing Act of 2018.	HOUSE OF REPRESENTATIVES,SENATE	10000		0	0	2018-07-18T18:09:20.823000-04:00